A group of nine authors involved with TransCelerate BioPharma Inc. will be honored with a Global Inspire Award at DIA’s upcoming Annual Meeting. DIA’s Global Inspire Award program recognizes the organization’s outstanding volunteers for their leadership, level of excellence, and commitment to service on a global scale.  

The recipients of the Author(s) of the Year Award, which acknowledges an author or group of authors whose article has made a significant impact in advancing medical product development, published “Defining a Central Monitoring Capability: Sharing the Experience of TransCelerate BioPharma's Approach, Part 1,” in  DIA’s official, scientific, peer-reviewed journal, Therapeutic Innovation & Regulatory Science. This award will recognize their published article as the most widely read article of the DIA publications in 2014.   

The article provides a description of how companies are deploying central monitoring in clinical trial quality management and provides samples of the workflows that illustrate how some have implemented it. The paper describes the initial implementation steps designed to learn what organizational capabilities are necessary.

“Improving clinical trial quality management is essential to ensure we have the best and most accurate data emerging from clinical trials as possible,” said Barbara Lopez Kunz, DIA global chief executive. “TransCelerate’s efforts to take the lead on improving this process, using its unique structure that unites biopharmaceutical companies across the world in mutual efforts to advance science, is an important model in our industry.”

Brett Wilson, BSP, Associate Director, Bristol-Myers Squibb Company and Andy Lawton, ASTAT, Global Head, Clinical Management, Boehringer Ingelheim, Ltd. will accept the award on behalf of the article authors.

Additional author winners include: Tom Provencher, BS, Senior Director, Clinical Trial Support and Compliance, UCB Pharma.; Jacqueline Gough, MMath, Central Monitoring, Clinical Development Innovation, Eli Lilly and Company; Stephanie Clark, MA, Research Officer/Board Member, ADHD-Europe, Janssen Pharmaceutical Companies, Ramil Abdrashitov, MD, PhD, MBA, Site Management and Monitoring, Clinical Operations, Global Medicines Development, AstraZeneca; Karolien de Roeck, MS, Clinical Director, AbbVie; Sarah Jane Constantine, MS, Senior Manager, Clinical Trial Oversight and Compliance, Cubist Pharmaceuticals; and David Knepper, MS, MBA, Quality Management Systems &Training, Actavis.

TransCelerate BioPharma Inc., launched in 2012, collaborates across the biopharmaceutical research and development community to identify, prioritize, design and facilitate the implementation of solutions to drive efficient, effective and high-quality delivery of new medicines, improving the health of people around the world. For more information about TransCelerate, click here.

For more information about DIA’s Inspire Award program, click here.

Registration is open to attend DIA’s 2015 51st Annual Meeting in Washington, D.C. June 14-18. Follow DIA’s Twitter feed (@DrugInfoAssn) and #DIA2015 for news about DIA 2015 51st Annual Meeting.